OCT 598
Alternative Names: KNP-502; OCT-3598; OCT-598Latest Information Update: 12 Jun 2023
At a glance
- Originator Kanaph Therapeutics
- Developer Kanaph Therapeutics; Oscotec
- Class Antineoplastics; Small molecules
- Mechanism of Action Prostaglandin E EP2 receptor antagonists; Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Solid tumours in South Korea (unspecified route)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 12 Oct 2020 Kanaph Therapeutics plans preclinical development in Solid tumours in early 2021